Navigation Links
Gentium's Defibrotide Highlighted in Poster Presentation at World,Congress of Nephrology

VILLA GUARDIA (COMO), Italy--(BUSINESS WIRE)--Apr 23, 2007 - Gentium S.p.A. (NASDAQ: GENT) (the "Company") today reported that its lead product, Defibrotide, will be the subject of a poster presentation at the World Congress of Nephrology 2007 being held in Rio de Janeiro, Brazil from April 21-25, 2007.

On Monday, April 23, 2007, Cinara Echart, Ph.D., Manager of Biological Research Laboratory at Gentium, will present a poster entitled "Defibrotide Modulates Glucose-Induced Heparanase Expression In Endothelial Cells: A Potential Mechanism Of Anti-Diabetic Activity" (Abstract #1382).

Diabetic nephropathy is characterized by a loss of glomerular basement membrane (GBM) integrity, which is a major cause of end-stage renal failure. Heparanase plays a key role in this aberrant remodeling of the GBM and has been shown to be up-regulated by hyperglycemic conditions such as found in diabetic patients.

Discussing the results, Dr. Echart said, "Our data suggests that Defibrotide not only has an effect on the down-regulation of heparanase gene expression, but also decreases its enzymatic activity in endothelial cells. Since heparanase is a critical factor in maintaining GBM integrity and is elevated in diabetic nephropathy, it should be considered for the management of this disease."

Laura Ferro, M.D., Gentium's president and chief executive officer, said, "These preclinical results are very exciting and encourage us to pursue further studies of Defibrotide's therapeutic potential in the management of diabetic nephropathy, a chronic disease for which there are limited treatment options. Further encouraging is that these data corroborate recently reported preclinical data showing Defibrotide to suppress heparanase expression and heparanase enzymatic activity in multiple myeloma cell lines."

It has previously been reported that Defibrotide, a polydisperse oligonucleotide with anti-thrombotic, thro
'"/>




Page: 1 2 3

Related medicine technology :

1. Gentiums Defibrotide Seen as Active in Multiple Myeloma
2. Gentiums Defibrotide Highlighted in Two Poster Presentations at American Association for Cancer Research Annual Meeting
3. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
4. Isotechnikas Lead Drug, ISA247, To Be Highlighted at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
5. Aeolus Pharmaceuticals AEOL 10150 Highlighted in Nature Genetics Publication
6. Alfacells Onconase Highlighted in Latest Edition of Handbook of Therapeutic Antibodies
7. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
8. Labopharm to Present Poster on Dose Titration of Once-daily Tramadol at 3rd International Forum on Pain Medicine
9. Keryx Biopharmaceuticals, Inc. Announces Poster Presentations Highlighting Mechanism of Action and Clinical Activity of Sulonex(TM) (sulodexide oral gelcap) at the Upcoming American Diabetes Association 67th Scientific Sessions in Chicago, Illinois
10. VeroScience Late-Breaking Abstract on Cycloset (A Quick Release Formulation of Bromocriptine Mesylate) Accepted for Poster Presentation at American Diabetes Association 67th Scientific Sessions
11. Savient Pharmaceuticals Announces Acceptance of Two Gout-Related Abstracts for Poster Presentation at the European League Against Rheumatism (EULAR) 2007 Annual Congress
Post Your Comments:
(Date:9/19/2014)... Sept. 19, 2014 The Parenteral Drug Association ... global post-approval changes protocols. The new ... topic expressed by industry participants and regulatory authority representatives ... month in Washington, DC . Representatives ... hand for the workshop. Attendees indicated openness to engaging ...
(Date:9/19/2014)... 19, 2014 /PRNewswire-iReach/ -- "United States ... provides key market data on the ... The report provides value, in millions ... units) within market categories – Bronchoscopes, ... & Gastroscopes, Duodenoscopes, Laparoscopes, Hysteroscopes, Sinuscopes, ...
(Date:9/19/2014)... 2014  The board of directors of AbbVie Inc. ... dividend of $0.42 per share.  The ... of record at the close of business on Oct. ... global, research-based biopharmaceutical company formed in 2013 following separation ... expertise, dedicated people and unique approach to innovation to ...
Breaking Medicine Technology:PDA Launches Effort to Harmonize Global Post-Approval Changes Protocols 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 2United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 3United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 4United States General Surgery Devices Market to 2020 - Endoscopy, Bariatric Surgery, Aesthetic Lasers and Energy, Biopsy Devices, Hernia Repair, Non-Vascular Stents 5
... Calif., Sept. 24 Amgen (Nasdaq: AMGN ... PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from ... precaution.  The product that is being recalled may contain ... in most cases. The lamellae result from the interaction ...
... BIOD ) announced today that it will be presenting at the ... Conference, September 28, 2010 at 12:00 pm Eastern time at the ... access a link to the live webcast of the presentation from ... . Replays of the presentation will be available for 90 days. ...
Cached Medicine Technology:Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 2Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 3Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 4Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 5Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 6Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 7Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 8Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 9Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 10Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 11Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 12Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 13Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 14Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 15Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 16Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 17Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 18Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 19Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 20Amgen Initiates Voluntary Nationwide Recall of Certain Lots of EPOGEN® and PROCRIT® (Epoetin alfa) 21
(Date:9/20/2014)... 2014 "As a nurse, patients always ask ... an inventor from Tamaqua, Pa. "The reason that they cannot ... of their chairs. My invention enables them to check oxygen ... Sensor to make it easier to monitor the contents of ... when the tank is low. It allows changeovers to be ...
(Date:9/20/2014)... Angeles, CA (PRWEB) September 20, 2014 ... score of 3.1 out of 5, indicating a moderately ... firm IBISWorld, this score reflects current and future pricing ... from historically high prices. Other factors that negatively affect ... in demand for construction and the moderate switching costs. ...
(Date:9/20/2014)... Wisconsin (PRWEB) September 20, 2014 QueenBeeTickets.com ... the young star’s tour performances. She will visit many ... of February until the 16th of April. , ... Grande Honeymoon Tour tickets at QueenBeeTickets.com. , The star’s ... opportunity to see their favorite young singer in a ...
(Date:9/20/2014)... 20, 2014 Final Cut Pro X ... release of the Information theme for FCPX filmmakers. , “Fun, ... describe the Information theme,” says Christina Austin, CEO of Pixel ... so professional.” , Information features easy to use controls that ... the environment. Change the background color, color of each circle ...
(Date:9/20/2014)... The first federal bellwether trial of a DePuy ... in the U.S. District Court, Northern District of Texas, ... the week opened in the DePuy Pinnacle Hip ... vice president, who discussed the clinical testing performed on ... According to Reuters, the executive stated that the Pinnacle ...
Breaking Medicine News(10 mins):Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 2Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 3Health News:Plumbing Construction Services Procurement Category Market Research Report from IBISWorld Has Been Updated 4Health News:Discount Ariana Grande Tickets: QueenBeeTickets.com Delights Fans with Discount Concert Tickets for Ariana Grande’s 2015 Honeymoon Tour 2Health News:Today Pixel Film Studios Announced the Release of the Information Theme for Final Cut Pro X 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 2Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 3Health News:Third Week of DePuy Pinnacle Hip Lawsuit Trial Focuses on Clinical Testing of Metal-on-Metal Hip Implant, Wright & Schulte LLC Reports 4
... disease ... ATLANTA, Nov. 12 One year following the launch of,operations ... Care,Improvement Plus feel their health has maintained or improved, according ... regional,membership. Of those who feel health has improved, 97 percent ...
... give patients a new lease on life. , ... ... back pain are reaching out to an innovative solution helping them ... With facilities in Tampa and Scottsdale, the Laser Spine Institute is ...
... official,breaking news service for North American companies participating in MEDICA,2008, ... The profile of Hokanson follows below., ... 9 /C 02 Web URL : ... the early 1970,s to provide the,instruments for Dr. Eugene Strandness, ...
... Technologies, IntelliFill i.v. robot to ... reduces errors and hospital ... Technologies,Inc., a pioneer in medication error reduction and hospital ... robotic I.V. dose,preparation system, IntelliFill i.v.(TM), by the Alegent ...
... survey shows health improvements, disease ... of plan -, SAN ANTONIO, Nov. 12 One ... members of Care Improvement Plus feel,their health has maintained or ... plan,s statewide membership. Of those who,feel health has improved, 97 ...
... Bioef are taking part in a European project the goal ... revolutionise the manner of controlling flu epidemics internationally, thanks to ... from the current 24 hours to a period of between ... number of control points. This research, in which other European ...
Cached Medicine News:Health News:Georgia and South Carolina Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 2Health News:Laser Spine Institute Helping Patients to "Stand Up and Be Free" from Debilitating Back Pain 3Health News:Hokanson Exhibiting at MEDICA 2008 2Health News:Alegent Health System Automates I.V. Preparation to Enhance Patient Safety 2Health News:Texas Care Improvement Plus Members Overwhelmingly Pleased with Special Needs Plan 2Health News:Design of system that will revolutionize control of influenza epidemics 2
... scaleable device that works with ... plasma or buffy coat. The ... must be prepared independently using ... volume and concentration factor can ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical....
The SB Charit is a prosthesis system consisting of two endplates made of high quality cobalt chromium alloy with an ultra high molecular weight polyethylene sliding core placed between them....
... The D185 is ... FDA clearance for this ... transcranial motor evoked potentials ... surgical procedures such as ...
Medicine Products: